Degroof Petercam – IMAP Belgium acted as Joint Global Coordinator in Oxurion’s successful €10 million private placement of new shares
The company intends to use the net proceeds to progress on the development of its two clinical stage assets, THR-149 and THR-687, which are currently in Phase 2 clinical trials for DME
Degroof Petercam - IMAP Belgium has acted as Joint Global Coordinator in the €10 million private placement of new shares of Oxurion.
Oxurion successfully raised €10 million in a private placement via a PIPE, offering 7,226,039 new shares which translated into a capital increase of 18.34%. The shares were placed on March 3, 2022 at a price of € 1.44 per share. The new shares were acquired by leading European and US healthcare investors.
The company intends to use the net proceeds to progress on the development of its two clinical stage assets, THR-149 and THR-687, which are currently in Phase 2 clinical trials for DME, with THR-149 for second line treatment and THR-687 for first line treatment.
The Degroof Petercam team, led by Erik De Clippel, acted as Joint Global Coordinator to Oxurion. This deal further consolidates Degroof Petercam’s franchise in Healthcare and expertise in private placements, and breaks new ground as the first-ever underwritten PIPE transaction in Belgium.